Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.64 |
| ▸ | AGXT | P21549 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 10/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29830809 | 1.00 | IDO1 (0.64) | IDO1AGXTMAOBTAAR1ALDH1A1 | |
| SCHEMBL511200 | 0.84 | IDO1 (0.56) | IDO1AGXTMAOBTAAR1ALDH1A1 | |
| SCHEMBL487468 | 0.84 | IDO1 (0.48) | IDO1AGXTMAOB | |
| SCHEMBL11019421 | 0.83 | IDO1 (0.60) | IDO1AGXTMAOBTAAR1ALDH1A1 | |
| SCHEMBL27037812 | 0.83 | IDO1 (0.55) | IDO1AGXTMAOBTAAR1ALDH1A1 | |
| SCHEMBL1767187 | 0.82 | IDO1 (0.69) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL30487709 | 0.79 | IDO1 (0.60) | IDO1AGXTMAOBTAAR1ALDH1A1 | |
| SCHEMBL2808421 | 0.79 | TAAR1 (0.57) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL30739138 | 0.79 | TAAR1 (0.57) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL8132483 | 0.79 | IDO1 (0.60) | IDO1AGXTMAOBTAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | claimed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | claimed |
| EP-4637754-A2 | SELECTIVE BET INHIBITORS AND USES THEREOF | Tay Therapeutics Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| WO-2025040546-A1 | PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS | PROXYGEN GMBH (AT) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024138201-A2 | SELECTIVE BET INHIBITORS AND USES THEREOF | Tay Therapeutics Limited (GB) | 2024-06-27 | — | — | WO | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| WO-2023244817-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-0985663-A1 | A 3.7-dithiaprostanoic acid derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5972946-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0826673-A1 | ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0003261-B1 | OXADITHIADIAZAPENTALENES, THEIR PREPARATION, FUNGICIDAL COMPOSITIONS CONTAINING THEM AND THE CONTROL OF FUNGI USING THEM | CHEVRON RESEARCH COMPANY (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4179441-A | REACTING SULFUR HALIDE WITH N-CYANOMETHYLCARBOXAMIDE; CYCLIZATION | CHEVRON RESEARCH COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| EP-0003261-A1 | Oxadithiadiazapentalenes, their preparation, fungicidal compositions containing them and the control of fungi using them | CHEVRON RESEARCH COMPANY (US) | 1979-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | FPR1, FPR2, FPR3 | IDO1 798/4885AGXT 2808/4885MAOB 1570/4885 |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | CKS1B, CSNK1A1, CKS2 | IDO1 1592/4885AGXT 3367/4885MAOB 4157/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | IDO1 1385/4885AGXT 3468/4885MAOB 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.